Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Otsuka Holdings Co., Ltd. TSE:4578
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.